The risk of blood clots is a serious concern worldwide, with venous thrombosis being one of the most common causes of death globally. A recent study from Lund University in Sweden has shed light on three genetic variants that significantly increase the risk of blood clots in the leg by up to 180%.

While arterial and venous blood clots have different causes and consequences, understanding the risk factors is crucial for prevention and treatment. In Sweden, over 10,000 people suffer from venous thromboembolism each year, with age being a strong risk factor.

“Venous thrombosis is a common disease that has always been somewhat overshadowed by arterial blood clots,” says Bengt Zöller, a specialist in general medicine at Skåne University Hospital and professor of general medicine at Lund University. “However, it’s essential to acknowledge its significance and take steps to prevent it.”
The risk factors for venous thrombosis include age, being overweight or tall, and lack of physical activity. Smoking is considered only a weak to moderate risk factor, while high blood pressure and high levels of blood lipids are associated with arterial clots, not venous ones.

Research suggests that commercial fishermen have a lower risk due to their diet rich in omega-3 fatty acids. Additionally, ultra-processed foods have been linked to an increased risk of blood clots, whereas plant-based diets may reduce this risk.
“Prophylaxis in the form of blood thinners may be particularly important if other risk factors are also present,” advises Zöller.

The three genetic variants identified by Bengt Zöller and his fellow researchers are ABO, F8, and VWF. These variants increase the risk of venous blood clots by 10-30% each, with an individual having five of these gene variants having a 180% higher risk.
“These genetic variants are present in all populations, making it essential to investigate how the number of risk genes affects the duration of treatment with anticoagulants after a blood clot,” concludes Zöller.

To prevent blood clots, one can take steps such as maintaining physical activity, monitoring blood pressure and lipid levels, quitting smoking, and eating a balanced diet rich in omega-3 fatty acids. Tailoring treatment based on risk assessment will become increasingly important in the future.
“Tailoring treatment based on risk assessment will become increasingly important,” concludes Bengt Zöller.

In summary, understanding the three genetic variants that increase the risk of blood clots by up to 180% is crucial for prevention and treatment. By acknowledging these risk factors, individuals can take steps to reduce their likelihood of developing venous thrombosis.
“Blood clot prevention is a vital aspect of healthcare, and awareness about the risks is essential,” emphasizes Zöller.

The production of green hydrogen is set to play an increasingly important role in the future energy system, offering a nearly climate-neutral way to store chemical energy and produce climate-friendly fuels. However, one of the bottlenecks in this process is the oxygen evolution reaction (OER), which requires special catalysts to speed up the formation of hydrogen and oxygen at the electrodes.

Current catalysts are made from precious metals, but these are rare and expensive, limiting their use for large-scale industrial applications. Researchers at the Helmholtz-Zentrum Berlin (HZB) have now identified a promising alternative: MXene structures that can host catalytically active particles to enhance the oxygen evolution reaction.

MXenes are flaky structures made of carbon and transition metals, which can be used as carriers for embedding catalytically active particles. A team led by Michelle Browne at HZB has developed sophisticated variants of these materials, using different vanadium carbide MXene variants as the basis for their research.

One variant, V2CTx with 10% vanadium vacancies, was found to have a significantly larger internal surface area than the pure MXene. This structure was then embedded with Co0.66Fe0.34 catalyst particles using a multi-step chemical process in Michelle Browne’s laboratory at HZB.

The resulting material showed a significant enhancement in catalytic activity compared to the pure iron-cobalt compound, and further improved efficiency when used as a carrier for the catalytically active particles. The team was able to track changes in the oxidation numbers of cobalt and iron during the electrolytic reaction using in situ X-ray absorption spectroscopy at the SOLEIL synchrotron source.

The results provide initial insights into the complex interplay between the carrier structure, the embedding of catalytically active particles, and catalytic activity. MXene is a promising candidate for the development of innovative, highly efficient, and inexpensive catalysts, and its use as a carrier material could revolutionize the production of green hydrogen.

As Michelle Browne emphasizes, “Currently, the industry has not yet considered MXene as a carrier material for catalytically active particles on the radar. We are conducting basic research here, but with clear prospects: on applications.” The study’s first author, Can Kaplan, adds that their results make the technology really meaningful and interesting for industrial applications.

The potential of MXene catalysts to accelerate the oxygen evolution reaction and boost green hydrogen production is a promising path forward in the energy transition. With further research and development, these materials could play a crucial role in making green hydrogen more viable and cost-effective, ultimately contributing to a more sustainable energy future.

The human body has a clever way of defending itself against bacterial pathogens by depriving them of vital nutrients like iron. This strategy, however, doesn’t always work against Salmonella, a bacterium responsible for typhoid fever. Researchers at the University of Basel have made an important discovery that sheds light on how these bacteria evade the immune system.

In a study published in Cell Host & Microbe, Professor Dirk Bumann’s team found that Salmonella specifically targets iron-rich regions within immune cells to replicate. This means that instead of being starved out by iron deprivation, the bacteria find a way to tap into the available iron and continue growing.

The body uses the transport protein NRAMP1 to pump iron out of the bacteria’s hiding place in immune cells. However, Salmonella has found a way to circumvent this strategy by infecting macrophages that reside in areas rich in red blood cell remnants. These macrophages contain high levels of iron, which the bacteria exploit to keep growing.

The researchers analyzed single-cell populations and discovered two distinct groups of Salmonella within these macrophages. One group resides in iron-poor regions and struggles to survive, while another subset thrives in vesicles rich in red blood cell remnants, where NRAMP1 transporters remove excess iron for recycling.

Even with over 99% of the iron being pumped out, the small remaining amount is still enough for the bacteria to keep growing. This finding highlights the importance of studying infections at the single-cell level and understanding how pathogens adapt and evade the immune defense mechanism.

The discovery provides important insights into host-pathogen dynamics and emphasizes the need to find effective ways to combat infections. By understanding how Salmonella outsmarts the immune system, researchers can develop new strategies to prevent and treat typhoid fever and other bacterial diseases.